Literature DB >> 33861984

SIRT2 and SIRT3 expression correlates with redox imbalance and advanced clinical stage in patients with multiple myeloma.

Alessandro Allegra1, Vanessa Innao2, Francesca Polito3, Rosaria Oteri4, Angela Alibrandi5, Andrea Gaetano Allegra2, Giacomo Oteri3, Rosa Maria Di Giorgio4, Caterina Musolino2, M'hammed Aguennouz4.   

Abstract

OBJECTIVES: Sirtuins comprise seven family elements (SIRT1-7) involved in various cell signalling pathways comprising cancer inhibition and tumorigenesis. The present study aims to evaluate SIRT2 and SIRT3 gene expression and potential redox reactions in patients with multiple myeloma (MM) at onset and its correlation with disease status, extent and presence of organ damage secondary to myeloma. DESIGN &
METHODS: Total RNA was extracted from 17 MM patients and 10 controls to assess gene expression using real-time PCR. The NAD+/NADH ratio as well as the levels of glutathione peroxidase (GPx) and hydrogen peroxide (HP) in peripheral blood mononuclear cells (PBMCs) were determined using established biochemical assays.
RESULTS: SIRT2 and SIRT3 expression is reduced in MM patients compared to healthy controls. Correlational analysis demonstrated that SIRT2 reduction is associated with advanced clinical stage and with more advanced bone lesions than in the remaining patients. SIRT3 expression is correlated with lytic bone lesions. Biochemical analysis indicated an imbalance of oxidative stress biomarkers with low concentrations of the antioxidant enzyme GPx, low amounts of NAD + and higher concentrations of pro-oxidant enzyme HP in PBMCs of MM patients compared to controls. Moreover, MM patients with bone lesions had lower concentrations of NAD + and GPx in PBMCs than patients without signs of bone disease. In addition, MM patients had higher quantities of intracellular HP than controls.
CONCLUSIONS: Our results demonstrate that SIRT2 and SIRT3 are downregulated in MM and that lower concentrations correlate with an advanced stage of disease and redox imbalance. We conclude that SIRT2 and SIRT3 together with oxidative stress biomarkers, may be useful for improved risk stratification of MM patients.
Copyright © 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deacetylases; Multiple Myeloma; NAD; Posttranslational changes; Sirtuin2; Sirtuin3

Year:  2021        PMID: 33861984     DOI: 10.1016/j.clinbiochem.2021.04.002

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  4 in total

1.  SIRT2-KLF4 Interactions are Critical for Myeloma Survival and Migration.

Authors:  Chunjuan Lu; Jin Wei
Journal:  Comput Intell Neurosci       Date:  2022-05-27

2.  Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway.

Authors:  Kuen-Jang Tsai; Hsin-Yi Tsai; Chin-Chuan Tsai; Tai-Yu Chen; Tsung-Hua Hsieh; Chun-Lin Chen; Lulekiwe Mbuyisa; Yaw-Bin Huang; Ming-Wei Lin
Journal:  Molecules       Date:  2021-10-26       Impact factor: 4.411

Review 3.  Role of Sirtuins in the Pathobiology of Onco-Hematological Diseases: A PROSPERO-Registered Study and In Silico Analysis.

Authors:  João Vitor Caetano Goes; Luiz Gustavo Carvalho; Roberta Taiane Germano de Oliveira; Mayara Magna de Lima Melo; Lázaro Antônio Campanha Novaes; Daniel Antunes Moreno; Paola Gyuliane Gonçalves; Carlos Victor Montefusco-Pereira; Ronald Feitosa Pinheiro; Howard Lopes Ribeiro Junior
Journal:  Cancers (Basel)       Date:  2022-09-23       Impact factor: 6.575

Review 4.  Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma.

Authors:  Alessandro Allegra; Claudia Petrarca; Mario Di Gioacchino; Marco Casciaro; Caterina Musolino; Sebastiano Gangemi
Journal:  Antioxidants (Basel)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.